Phibro Animal Health (PAHC) Stifel Jaws & Paws Conference 2025 summary

Strategic acquisitions and integration

• Achieved significant growth through the acquisition of Zoetis' medicated feed additive (MFA) business, increasing pro forma sales from $1 billion to $1.4 billion and expanding EBITDA margins into the mid to high 20% range.

• Integration of the acquired business has been seamless, with rapid transfer of marketing authorizations, especially in the U.S., and positive customer feedback.

• The acquisition strengthened presence in beef and swine segments and re-established a base in Europe, now a key growth market.

• The company is now the number two player in MFAs, with a more balanced portfolio across poultry, beef, dairy, and swine.

• Opportunities identified for further cost efficiencies and product combination approvals to enhance value.

Financial performance and outlook

• Fiscal year 2024 sales reached $1 billion organically, with guidance for $1.26–$1.29 billion including the acquisition; EBITDA guidance is $177–$183 million.

• Legacy business sales and EBITDA are up 8% and 26% year-over-year, respectively, through Q3.

• Achieved leverage target of below 3x EBITDA two years ahead of plan, with continued focus on debt reduction.

• The Phibro Forward transformation initiative is driving income growth through cost and sales levers, with greater impact expected in 2026.

• Anticipates headwinds from tariffs ($5–$10 million EBITDA impact) and changes in bank financing, but remains confident in growth prospects.

Product portfolio and innovation

• Core business spans medicated feed additives, nutritional specialties, and vaccines, with a strong focus on animal health and welfare.

• Expanded product offerings in antimicrobials, anti-coccidials, ionophores, and rumen function products, especially for poultry and cattle.

• Nutrition specialties target ruminants and monogastrics, with branded products supporting gut health and performance.

• Vaccine portfolio includes conventional, autogenous, and adjuvant products, with custom solutions for poultry and other livestock.

• R&D investment is about 3–4% of animal health sales, embedded in SG&A, supporting pipeline development for emerging diseases.